NCT07424781Recruiting
Fluoxetine on Emotional Experience (FLEX) Study
The Effect of Fluoxetine Treatment on Anger Processing in Healthy Young People
Source: ClinicalTrials.gov · Last updated 20 Feb 2026
Brief summary (registry, in English)
The goal of this clinical medicine study is to investigate how does antidepressant fluoxetine modulate anger processing in healthy young people . The main questions it aims is to answer are: 1. How does fluoxetine affect responses to anger-related stimuli such as words, faces, and autobiographical recall? 2. How does fluoxetine influence responses during frustration induction in frustrative non-reward and threat paradigms? 3. Does the effect manifest in physiological markers, including heart rate variability and facial expressions? Researchers will compare fluoxetine to a placebo to see if drug fluoxetine affects anger processing. Participants will: Take 20mg fluoxetine or a placebo every day for 7 days. Visit the university site for questionnaire and tasks assessments. Heart rate variability and facial expressions will be recorded in some of the tasks.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 3 Dec 2025
- Start date
- 1 Oct 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- University of Oxford
- Diseases
- Depression
- NCT number
- NCT07424781
What you commit to
- Study type: Interventional
- Planned participants: 80
- From 1 Oct 2025 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current or recent use (in the last 3 months) of any psychoactive substance according to self-report and a urine drug test screening for recent use of 10 common recreational substances;
- Physical Health:
- Current or recent use of medication that might interfere or interact with the effects of fluoxetine, in the opinion of the study medical advisor, including but not limited to: monoamine oxidase inhibitors (MAOIs), medications affecting serotonin levels (e.g., tramadol, triptans, St. John's Wort), anticoagulants or blood thinners (e.g., warfarin), anti-inflammatory medications (e.g., aspirin, ibuprofen), or medications known to affect heart rhythm;
- Prior Study Participation:
- Participation in any other psychological or medical experiment involving taking any kind of drug/medication/vaccine, within the last 3 months;
Other illness
- Psychiatric History:
- Current or past diagnosis of any psychiatric disorder, as determined by the Structured Clinical Interview for the DSM-5 (SCID-5) and self-report. This includes, but is not limited to, depression, anxiety disorders, alcohol or drug dependency, personality disorders, suicidal ideation, and other psychiatric conditions;
- Known contraindication to fluoxetine, such as hypersensitivity to fluoxetine or any component in its formulation;
- Past or ongoing health issue which, in the opinion of the study medical advisor, may interfere with the safety of the participant or the scientific integrity of the study, including but not limited to: seizures or epilepsy, heart rhythm problem, renal disease, hepatic disease, glaucoma, diabetes, bleeding disorders or clotting conditions (e.g., haemophilia, thrombocytopenia);
- Diagnosis of a significant neurological condition (e.g., epilepsy, multiple sclerosis, traumatic brain injury).
- Diagnosis of a neurodevelopmental condition, such as autism spectrum disorder (ASD) or attention-deficit/hyperactivity disorder (ADHD);
Other
- The participant may not enter the study if ANY of the following apply:
- First degree relative with a diagnosis of mania;
- Lifestyle:
- Heavy smoker or vaper (\> 10 cigarettes per day, or \>2 mL e-liquid, or \>15mg/day from a nicotine patch);
- Heavy use of caffeine (drink \> 4 of 250ml cups/cans of coffee or energy drinks per day);
- Heavy drinker (drink \>14 standard alcoholic drinks per week);
- Severely underweight or overweight in a manner that renders them unsuitable for the study in the opinion of the study medical advisor;
- Pregnancy, as determined by a urine pregnancy test or plans to become pregnant within the next 3 months;
- Breastfeeding;
- Not able to consume gelatine;
- Medical History:
- Participation in any other study involving the current or similar tasks, within the last 6 months;
- Others
- •Any other significant finding which may arise during the screening process and which, in the opinion of the Principal Investigator/medical advisor, may influence the scientific integrity of the study, or the participant's ability to participate in the study.
Who the study is looking for
- Be aged 18-24 years (inclusive)
- Be resident in the UK for the duration of the study
- Have normal or corrected to normal vision
- Participant is willing and able to give informed consent for participation in the research
- Sufficiently fluent English to understand and complete the study
Age in the registry: 18 years to 24 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Psychiatry, University of Oxford Coordinator of this site? Confirm its status | Oxford | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.